Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2023-03-27 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力独立董事关于公司与关联方资金往来以及对外担保情况的专项说明及独立意见
Regulatory Filings Classification · 95% confidence The document is a special statement and independent opinion from independent directors regarding the company's related party transactions and external guarantees for the fiscal year 2022. It references compliance with regulations and internal company rules, and provides an independent directors' opinion on these matters. The document is relatively short (918 characters) and focuses on governance and compliance issues rather than presenting full financial statements or audit results. It is not an annual report, audit report, or financial statement. Instead, it is a governance-related disclosure concerning related party transactions and guarantees, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories and is a compliance-related statement.
2023-03-27 Chinese
天士力2022年度利润分配预案
Notice of Dividend Amount Classification · 95% confidence The document is a profit distribution plan for the year 2022 by TianShiLi Pharmaceutical Group Co., Ltd. It details the proposed cash dividend per share, total dividend amount, and the decision-making process including board approval and independent director opinions. It also mentions the need for shareholder approval at the annual general meeting. The document is an announcement of the dividend distribution plan rather than the actual dividend payment notice or the full annual report. It is not a full financial report but a specific announcement related to dividend distribution. Therefore, it fits best under the category of Notice of Dividend Amount (DIV). The document length is 1667 characters, which is short and focused on dividend distribution details, supporting this classification.
2023-03-27 Chinese
天士力第八届董事会第18次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding various reports and proposals related to the 2022 fiscal year, including the general manager's work report, board work report, audit committee report, financial statements, profit distribution plan, annual report, social responsibility report, internal control reports, and other related matters. It also references that the full reports are published on the Shanghai Stock Exchange website and that some proposals will be submitted to the 2022 annual shareholders meeting for approval. The document itself is relatively short (3200 characters) and primarily serves as a formal announcement of board meeting decisions and references to where the full reports can be found. This fits the pattern of a Declaration of Voting Results & Voting Rights Announcements (DVA) because it reports the voting outcomes of the board meeting on various agenda items, including approval of reports and proposals. It is not the full annual report or financial statements themselves, but an announcement of resolutions and voting results. Therefore, the correct classification is DVA with high confidence.
2023-03-27 Chinese
天士力2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the 2022 annual report summary of 天士力医药集团股份有限公司 (Tianshili Pharmaceutical Group Co., Ltd.). It contains detailed sections on company overview, management discussion and analysis, research and development progress, marketing strategies, manufacturing updates, and future plans. It includes comprehensive financial and operational data for the full fiscal year 2022, as well as audited profit distribution plans and dividend information. The length is substantial (15,000 characters), and it is not merely an announcement or a certification. The content matches the characteristics of an official yearly report covering company activity and full financial performance. Therefore, the document is classified as an Annual Report (10-K). FY 2022
2023-03-27 Chinese
天士力关于2023年度预计发生的日常经营性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's expected and actual related party transactions for the year 2023, including descriptions of the nature, pricing, counterparties, and impact of these transactions. It includes financial data and explanations about the necessity, fairness, and impact of these related party transactions on the company. The document is titled as an announcement and contains no financial statements or comprehensive financial performance data typical of annual or interim reports. It is not a report of voting results, management changes, or legal proceedings. The content fits the category of a regulatory announcement about related party transactions, which is a common type of regulatory filing in many jurisdictions. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-03-27 Chinese
天士力2022年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as the "2022年度独立董事述职报告" which translates to "2022 Annual Independent Directors' Report". It details the independent directors' activities, attendance at board and shareholder meetings, their opinions on company matters including related party transactions, guarantees, auditor appointments, dividend proposals, internal controls, and information disclosure. The content focuses on the independent directors' duties and their oversight role rather than presenting full financial statements or audit results. The document length is 3918 characters, which is relatively short and more of a report on board/management activities rather than a full annual report or audit report. It is not a call transcript, earnings release, or regulatory filing. It fits best under Board/Management Information (MANG) as it relates to the independent directors' report on their work and governance oversight for the year 2022.
2023-03-27 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.